Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03433885 |
|
Recruitment Status :
Recruiting
First Posted : February 15, 2018
Last Update Posted : February 24, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Macular Pigment Optical Density |
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly.[1] The disease is categorized into early, intermediate, or advanced stages based on the severity of symptoms. The advanced stage, including GA and CNV, involves central region of the retina, which leads to a gradual or rapid loss of photoreceptors and central vision.
The macular pigment (MP) consists of xanthophyll, which is formed from the yellow carotenoid lutein, zeaxanthin, and meso-zeaxanthin.These pigments play an important role in protecting the retina against oxidative stress through different mechanisms[6]. Many studies have shown a various association of AMD and MP.Blue Mountain Eye Study revealed low dietary intake of lutein and zeaxanthin is associated with a higher risk of AMD. However, dry and wet subtypes of AMD may have different etiologies and risk factors. Little is known whether longitudinal study of macular pigment optical density (MPOD) is related to AMD progression.
A comprehensive ophthalmologic examination including fundus photography,OCT and MPOD was performed at baseline, and semiannually thereafter for 3 years. Fundus reflectance (VISUCAM 500, reflectance of a single 460 nm wavelength) was used to measure the MPOD levels. Associated risk factors including body-mass index (BMI), smoking, diet, and cardiovascular diseases were documented. Drusen characteristics (size, type, area), pigmentary abnormalities (increased pigment, depigmentation, geographic atrophy), and presence of abnormalities characteristic of neovascular AMD were graded. For estimations of AMD progression , a 9-step severity scale that combines a 6-step drusen area scale with a 5-step pigmentary abnormality scale is used.
In this study, we are going to investigate a 3-year study of incidence and progression for AMD and associated risk factors, in a population-based cohort of Chinese aged 45 years and older living in the city of Wenzhou.
| Study Type : | Observational |
| Estimated Enrollment : | 300 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Progression of Dry Age-related Macular Degeneration (AMD): Association With Macular Pigment Optical Density (MPOD) |
| Actual Study Start Date : | January 1, 2018 |
| Estimated Primary Completion Date : | December 31, 2021 |
| Estimated Study Completion Date : | December 31, 2023 |
| Group/Cohort |
|---|
|
Progressors
Progressors are those individuals with early or intermediate AMD at baseline who progress to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progress to advanced AMD in both eyes.
|
|
Nonprogressor
Nonprogressors are those individuals with early or intermediate AMD at baseline who do not progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who do not progress to advanced AMD in fellow eye.
|
- Association between changes of macular pigment optical density (MPOD) level and incidence rates of advanced AMD [ Time Frame: from baseline to month 36 ]Incident advanced AMD was evaluated based on the AMD grade at the end of the clinical trial with follow-up time of 3 years. Progressors were those individuals with early or intermediate AMD at baseline who progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progressed to advanced AMD in both eyes
- Association between age and incident Advanced AMD [ Time Frame: baseline ]controlling for age (70 years or older versus younger than 70)
- Association between gender and incident Advanced AMD [ Time Frame: baseline ]
- Association between Baseline AMD grade and incident Advanced AMD [ Time Frame: baseline ]Baseline AMD grade was defined as AREDS category 1 in both eyes (essentially free of age-related macular abnormalities), category 2 in the worst eye (mild changes including multiple small drusen, nonextensive intermediate drusen, and/or pigment abnormalities), category 3 in the worst eye (at least one large drusen of at least 125µm diameter, extensive intermediate drusen, and/or noncentral geographic atrophy), category 4 in one eye (advanced AMD, either neovascular or central geographic atrophy, or visual loss due to AMD regardless of phenotype), or category 4 in both eyes.
- Association between cigarette smoking and incident Advanced AMD [ Time Frame: baseline ]
cigarette smoking information was acquired by questionaires(never, past, or current)
.
- Association between body mass index (BMI) and incident Advanced AMD [ Time Frame: baseline ]BMI was calculated as the weight in kilograms divided by the square of the height in meters ( 25, 25-29.9, and 30 )
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 45 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- subject is diagnosed with either CNV, dry AMD
- 45 years of age or older
- provides signed and dated informed consent
Exclusion Criteria:
- Ocular condition in the study eye which may impact vision and confound study outcomes
- Presence of macular edema like retinal vascular diseases or diabetic retinopathy
- active inflammation ofr infection in the study eye
- high myopia（ ≥6D ）
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03433885
| Contact: Rong Zhou, MD | 86-577-88068855 | zhourongmoon@163.com |
| China, Zhejiang | |
| The eye hospital of Wenzhou Medical University | Recruiting |
| Wenzhou, Zhejiang, China, 325000 | |
| Contact: Rong Zhou, MD | |
| Principal Investigator: Xiaoling Liu, MD | |
| Principal Investigator: | Xiaoling Liu, MD | The Eye Hospital of Wenzhou Medical University |
| Responsible Party: | Xiaoling Liu, Chief in retina center, The Eye Hospital of Wenzhou Medical University |
| ClinicalTrials.gov Identifier: | NCT03433885 |
| Other Study ID Numbers: |
kyk20175 |
| First Posted: | February 15, 2018 Key Record Dates |
| Last Update Posted: | February 24, 2021 |
| Last Verified: | February 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
macular pigment optical density (MPOD) Age-related Macular Degeneration (AMD) drusen |
Chroidal neovascularization (CNV) lutein zeaxanthin |
|
Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases |